These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

510 related items for PubMed ID: 20927745

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. WITHDRAWN: Terazosin for benign prostatic hyperplasia.
    Wilt TJ, Howe RW, Rutks I, Macdonald R.
    Cochrane Database Syst Rev; 2011 Sep 07; 2011(9):CD003851. PubMed ID: 21901686
    [Abstract] [Full Text] [Related]

  • 3. Terazosin for benign prostatic hyperplasia.
    Wilt TJ, Howe RW, Rutks IR, MacDonald R.
    Cochrane Database Syst Rev; 2002 Sep 07; (4):CD003851. PubMed ID: 12519611
    [Abstract] [Full Text] [Related]

  • 4. Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects.
    MacDonald R, Wilt TJ, Howe RW.
    BJU Int; 2004 Dec 07; 94(9):1263-70. PubMed ID: 15610102
    [Abstract] [Full Text] [Related]

  • 5. Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects.
    Wilt TJ, Howe W, MacDonald R.
    BJU Int; 2002 Feb 07; 89(3):214-25. PubMed ID: 11856101
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
    Logan YT, Belgeri MT.
    Am J Geriatr Pharmacother; 2005 Jun 07; 3(2):103-14. PubMed ID: 16129387
    [Abstract] [Full Text] [Related]

  • 8. Tamsulosin for benign prostatic hyperplasia.
    Wilt TJ, Mac Donald R, Rutks I.
    Cochrane Database Syst Rev; 2003 Jun 07; (1):CD002081. PubMed ID: 12535426
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
    McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA, Medical Therapy of Prostatic Symptoms (MTOPS) Research Group.
    N Engl J Med; 2003 Dec 18; 349(25):2387-98. PubMed ID: 14681504
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Serenoa repens for benign prostatic hyperplasia.
    Tacklind J, Macdonald R, Rutks I, Stanke JU, Wilt TJ.
    Cochrane Database Syst Rev; 2012 Dec 12; 12(12):CD001423. PubMed ID: 23235581
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA, McVary KT.
    Int J Impot Res; 2008 Dec 12; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia.
    Ohsfeldt RL, Kreder KJ, Klein RW, Chrischilles EA.
    J Manag Care Pharm; 2004 Dec 12; 10(5):412-22. PubMed ID: 15369424
    [Abstract] [Full Text] [Related]

  • 18. Medical therapy for benign prostatic hyperplasia: a review of the literature.
    Clifford GM, Farmer RD.
    Eur Urol; 2000 Jul 12; 38(1):2-19. PubMed ID: 10859436
    [Abstract] [Full Text] [Related]

  • 19. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
    Hwang EC, Gandhi S, Jung JH, Imamura M, Kim MH, Pang R, Dahm P.
    Cochrane Database Syst Rev; 2018 Oct 11; 10(10):CD007360. PubMed ID: 30306544
    [Abstract] [Full Text] [Related]

  • 20. Time Course of Incident Adverse Experiences Associated with Doxazosin, Finasteride and Combination Therapy in Men with Benign Prostatic Hyperplasia: The MTOPS Trial.
    Kaplan SA, Lee JY, Meehan AG, Kusek JW.
    J Urol; 2016 Jun 11; 195(6):1825-9. PubMed ID: 26678956
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.